Earnings summaries and quarterly performance for EyePoint.
Executive leadership at EyePoint.
Board of directors at EyePoint.
Research analysts who have asked questions during EyePoint earnings calls.
Yatin Suneja
Guggenheim Partners
7 questions for EYPT
Also covers: ACAD, ARGX, AXSM +10 more
YC
Yi Chen
H.C. Wainwright & Co.
6 questions for EYPT
Also covers: ANGO, APDN, BLFS +22 more
DC
Debanjana Chatterjee
JonesTrading Institutional Services
5 questions for EYPT
Also covers: ABSI, CLSD, KALV +2 more
Jennifer Kim
Cantor Fitzgerald
5 questions for EYPT
Also covers: BLTE, CPRX, INSM +1 more
Tessa Romero
JPMorgan Chase & Co.
5 questions for EYPT
Also covers: ACAD, AGIO, CYTK +5 more
YN
Yigal Nochomovitz
Citigroup Inc.
5 questions for EYPT
Also covers: ALDX, APLS, ARCT +22 more
CK
Colleen Kusy
Robert W. Baird & Co.
4 questions for EYPT
Also covers: APLS, BPMC, CHRS +5 more
Graig Suvannavejh
Mizuho Securities
4 questions for EYPT
Also covers: ADAP, ADVM, ALEC +11 more
GH
Greg Harrison
RBC Capital Markets
4 questions for EYPT
Also covers: ADCT, APLS, BBIO +3 more
KY
Kambiz Yazdi
Jefferies
4 questions for EYPT
Also covers: ARQT, LQDA, PRAX
TV
Tyler Van Buren
TD Cowen
4 questions for EYPT
Also covers: ADVM, ALLO, ARQT +12 more
Nick Quartapella
Robert W. Baird & Co.
3 questions for EYPT
YJ
Yale Jen
Laidlaw & Company (UK) Ltd.
3 questions for EYPT
Also covers: AFMD, ALDX, ARCT +13 more
DG
Daniil Gataulin
Chardan
2 questions for EYPT
Also covers: CGTX, CLSD, KOD +3 more
LW
Lisa Walter
RBC Capital Markets
2 questions for EYPT
Also covers: APLS, OCUL, RGNX +2 more
Gregory Harrison
Scotiabank
1 question for EYPT
Also covers: AGIO, APLS, GERN +3 more
GS
Greg Silvaniouve
Mizuho Financial Group
1 question for EYPT
GS
Greg Silvanouve
Mizuho
1 question for EYPT
Recent press releases and 8-K filings for EYPT.
EyePoint Provides Update on Duraview Clinical Trials and Financial Position
EYPT
New Projects/Investments
Guidance Update
- EyePoint's lead product, Duraview, is in Phase III trials for wet age-related macular degeneration (AMD), with both trials fully enrolled and top-line data anticipated mid-year 2026.
- The Duraview Phase III program for diabetic macular edema (DME) is underway, with the first patients expected to be dosed in Q1 2026.
- As of the end of 2025, EyePoint had approximately $300 million in cash, providing a financial runway past data into the end of 2027 and funding all ongoing Phase III trials.
- The company has a commercial manufacturing facility in Northbridge, Massachusetts, which has been operational for over a year and is preparing for pre-approval inspection and commercial success.
- Duraview is highlighted for its multi-mechanism of action (VEGF, PDGF, and IL-6 inhibition), at least six-month durability, and the convenience of room temperature storage.
8 days ago
EyePoint Provides Update on Duraview Phase III Trials and Financial Position at JPMorgan Healthcare Conference
EYPT
New Projects/Investments
Guidance Update
- EyePoint's lead product, Duraview, a sustained-release drug for retinal disease, is in Phase III trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
- The company anticipates top-line data from its wet AMD trials (Lugano and Lucia) starting mid-year 2026, and plans to dose the first patients in its DME trials (COMO and CAPRI) in Q1 2026.
- As of the end of 2025, EyePoint reported approximately $300 million in cash, providing a financial runway into Q4 2027, which funds all ongoing Phase III trials.
- Duraview is characterized by its multi-mechanism of action (MOA), targeting VEGF, PDGF, and IL-6, and demonstrated six-month durability in previous trials with a favorable safety profile.
8 days ago
EyePoint Provides Update on DURAVYU Clinical Trials and Financial Position
EYPT
New Projects/Investments
Guidance Update
- EyePoint's lead product, DURAVYU, is in Phase III trials for wet age-related macular degeneration (AMD) with top-line data expected starting mid-2026, and Phase III trials for diabetic macular edema (DME) are underway with first patients to be dosed in Q1 2026.
- The company reported approximately $300 million in cash as of the end of 2025, providing a financial runway well past data into the end of 2027.
- EyePoint's commercial manufacturing facility in Northbridge, Massachusetts, has been operational for over a year and is preparing for pre-approval inspection and commercial success.
- DURAVYU is a sustained-release drug for retinal disease, offering multi-MOA (VEGF, IL-6, PDGF inhibition) and six-month durability, with a non-inferiority regulatory pathway against Eylea.
8 days ago
EyePoint Pharmaceuticals Provides Update on DURAVYU™ Phase 3 Trials and Financial Runway
EYPT
New Projects/Investments
Guidance Update
- EyePoint Pharmaceuticals' DURAVYU™ (vorolanib intravitreal insert) Phase 3 trials for wet AMD are fully enrolled, with topline data anticipated in mid-2026.
- The Phase 3 DME program is underway, with First Patient In (FPI) expected in Q1 2026.
- The company reported approximately $300 million in cash and investments as of December 31, 2025, providing a runway into Q4 2027.
- DURAVYU™ has demonstrated a favorable safety profile with no related severe adverse events across four clinical trials and offers multi-MOA with 6-month durability for a combined $15B+ global market opportunity in wet AMD and DME.
8 days ago
EyePoint Investor Presentation Highlights DURAVYU Development
EYPT
New Projects/Investments
Guidance Update
Product Launch
- EyePoint's January 2026 investor presentation focuses on its product candidate, DURAVYU.
- DURAVYU is anticipated to be the first-to-market sustained release treatment for wet AMD and is the only TKI in development for DME, with expectations for two potential blockbuster indications.
- The company expects to provide updates on the timing for DME clinical trial enrollment and the availability of wet AMD clinical data.
- Key risks include uncertainties in clinical development, regulatory approval processes, and the sufficiency of the company's cash and cash equivalents.
Jan 12, 2026, 12:00 PM
EyePoint Reports Preliminary Cash and Key Clinical Milestones
EYPT
Guidance Update
New Projects/Investments
- EyePoint, Inc. reported preliminary cash and investments of approximately $300 million as of December 31, 2025, which is expected to provide a cash runway into the fourth quarter of 2027.
- The company completed an underwritten public offering in October 2025, generating $172.5 million in gross proceeds.
- Topline data from the Phase 3 wet Age-Related Macular Degeneration (AMD) program for DURAVYU is anticipated beginning in mid-2026.
- First patient dosing for the Phase 3 Diabetic Macular Edema (DME) program for DURAVYU is expected in Q1 2026.
Jan 7, 2026, 12:05 PM
EyePoint Pharmaceuticals Announces Positive DSMC Recommendation for DURAVYU Phase 3 Trials
EYPT
New Projects/Investments
Product Launch
- EyePoint Pharmaceuticals received a positive recommendation from the independent Data Safety Monitoring Committee (DSMC) for its pivotal Phase 3 program evaluating DURAVYU for wet age-related macular degeneration (wet AMD).
- The DSMC recommended that both the LUGANO and LUCIA trials continue as planned with no modifications to the protocol, citing no safety signals in the masked safety data.
- The company anticipates reporting topline 56-week data for the LUGANO trial in mid-2026, with LUCIA data to follow.
- First patient dosing for DURAVYU in Phase 3 trials for diabetic macular edema (DME) is expected in the first quarter of 2026.
Nov 19, 2025, 12:05 PM
EyePoint Pharmaceuticals Provides Update on DURAVYU™ Clinical Programs and Financial Position
EYPT
Product Launch
Guidance Update
New Projects/Investments
- EyePoint Pharmaceuticals reported a strong balance sheet with approximately $366 million in cash and equivalents as of September 30, 2025, providing a cash runway into Q4 2027, which extends beyond the anticipated Phase 3 wet AMD data and fully funds the DME pivotal program.
- The company's lead product, DURAVYU™, has two Phase 3 trials for wet AMD (LUGANO and LUCIA) fully enrolled, with initial data expected in mid-2026.
- For Diabetic Macular Edema (DME), the Phase 3 program for DURAVYU™ is underway, with the First Patient In (FPI) anticipated in Q1 2026. DURAVYU™ is positioned as the only TKI in development for DME.
- Commercial scale-up for DURAVYU™ is in progress at a 41,000 sq ft US manufacturing facility in Northbridge, MA, with registration batches underway to support a future NDA filing.
Nov 12, 2025, 3:40 PM
EyePoint Pharmaceuticals Provides Update on Phase 3 Trials and Financial Position
EYPT
New Projects/Investments
Guidance Update
- EyePoint Pharmaceuticals (EYPT) announced that its wet AMD Phase 3 trials are fully enrolled, with first top-line data expected mid-summer 2026.
- The company plans to initiate DME Phase 3 trials in Q1 2026, with top-line readouts for both DME trials anticipated in Q4 2027.
- EYPT highlighted its strong balance sheet with approximately $350 million in cash, providing a runway into Q4 2027 and covering all four Phase 3 trials.
- The Duravyu program, utilizing a multi-MOA drug (vorolanib) that blocks VEGF receptors and inflammation via JAK1, is positioned as a potential "first in class and best in class" treatment for wet AMD and DME.
Nov 12, 2025, 3:40 PM
EyePoint Provides Updates on Pivotal Wet AMD and Phase 3 DME Trials
EYPT
New Projects/Investments
Product Launch
Guidance Update
- EyePoint's two pivotal wet age-related macular degeneration (AMD) trials, Lugano and Lugia, are fully enrolled with over 400 patients each. The top-line readout for the Lugano Trial is expected mid-next year (2026), with the Lugia Trial results following shortly thereafter. The company aims for statistical non-inferiority to Eylea.
- The company plans to initiate two identical Phase 3 trials for diabetic macular edema (DME), COMO and COPRI, in Q1 next year (2026). Top-line results for these DME trials are anticipated in Q4 2027.
- EyePoint's drug, vorolanib, offers a multi-mechanism of action, providing both anti-VEGF and anti-inflammatory effects by blocking the JAK1 receptor and IL-6, which is considered a key differentiator, particularly in DME.
- EyePoint intends to self-launch the drug in the United States and will seek a global partner for ex-US markets, expecting to be first to file and first to market.
Nov 10, 2025, 3:30 PM
Quarterly earnings call transcripts for EyePoint.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more